COMP <GO>
RVMD vs GILD // ALTMAN Z-SCORE & DEBT/EQUITY
Revolution Medicines Inc. (NASDAQ) VS. Gilead Sciences Inc. (NASDAQ) • 15-METRIC TALLY: RVMD 3
— GILD 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: RVMD
LAST: $191.31 (+0.55%) • MKT CAP: $40.78B
balance-sheet
26.00
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
balance-sheet
5.87
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVMD VS. GILD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVMD | GILD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 78.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.60% | 21.00% | -49.60 | GILD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 4.60% | -6.84 | GILD | /fcf-yield <GO> |
| Operating Margin | — | 34.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 28.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 2.40% | +13.00 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.95% | -1.95 | GILD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 5.87 | +20.13 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | GILD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 64.3 | -16.50 | GILD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.88 | +0.19 | RVMD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 22.4x | +11.60 | GILD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.78B | $205.35B | -$164.57B | GILD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVMD REV | GILD REV | RVMD GROSS % | GILD GROSS % | RVMD FCF | GILD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $29.44B | — | 78.8% | -$913.7M | $9.46B |
| FY 2024 | $0 | $28.75B | — | 78.3% | -$567.7M | $10.30B |
| FY 2023 | $11.6M | $27.12B | — | — | -$351.1M | $6.79B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVMD // BETA 1.07
GILD // BETA 0.88